Deciphera Pharmaceuticals (STU:D05) EBIT per Share : €-2.22 (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Deciphera Pharmaceuticals EBIT per Share?

Deciphera Pharmaceuticals's EBIT per Share for the three months ended in Mar. 2024 was €-0.51. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €-2.22.

During the past 3 years, the average EBIT per Share Growth Rate was 20.10% per year. During the past 5 years, the average EBIT per Share Growth Rate was 7.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Deciphera Pharmaceuticals's EBIT per Share or its related term are showing as below:

STU:D05' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -55.9 Med: -18.85 Max: 20.1
Current: 20.1

During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Deciphera Pharmaceuticals was 20.10% per year. The lowest was -55.90% per year. And the median was -18.85% per year.

STU:D05's 3-Year EBIT Growth Rate is ranked better than
67.56% of 860 companies
in the Drug Manufacturers industry
Industry Median: 7.4 vs STU:D05: 20.10

Deciphera Pharmaceuticals's EBIT for the three months ended in Mar. 2024 was €-44.9 Mil.

Deciphera Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Deciphera Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deciphera Pharmaceuticals EBIT per Share Chart

Deciphera Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-4.04

-4.00

-4.57

-2.29

-2.27

Deciphera Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.60	-0.57	-0.59	-0.54	-0.51

Deciphera Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Deciphera Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-193.448	/	85.060
=	-2.27

Deciphera Pharmaceuticals's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-44.939	/	87.388
=	-0.51

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.22

Deciphera Pharmaceuticals (STU:D05) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Deciphera Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Deciphera Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Deciphera Pharmaceuticals (STU:D05) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Deciphera Pharmaceuticals Inc (STU:D05) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

DCPH:USA D05:Germany

Address

200 Smith Street, Waltham, MA, USA, 02451

Website

https://www.deciphera.com

Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.

Deciphera Pharmaceuticals (STU:D05) Headlines

No Headlines